Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.06.1101 on September 11 2006

Journal of Clinical Oncology, Vol 24, No 29 (October 10), 2006: pp. 4731-4737
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bepler, G.
Right arrow Articles by Simon, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bepler, G.
Right arrow Articles by Simon, G.

RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer

Gerold Bepler, Irina Kusmartseva, Swati Sharma, Ashish Gautam, Alan Cantor, Anupama Sharma, George Simon

From the Program and Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Address reprint requests to Gerold Bepler, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, MRC-4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: beplerg{at}moffitt.usf.edu

PURPOSE: RRM1 encodes the regulatory subunit of ribonucleotide reductase and is a molecular target of gemcitabine. Previous studies showed increased RRM1 expression on continuous exposure of cell lines to gemcitabine and suggested improved survival for patients with low as opposed to high tumoral RRM1 expression when treated with gemcitabine-containing chemotherapy. However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed.

PATIENTS AND METHODS: We constructed genetically modified lung cancer cell lines with increased and decreased RRM1 expression to investigate the in vitro 50% inhibitory concentration (IC50) for gemcitabine, cisplatin, and carboplatin. A prospective phase II clinical trial in patients with locally advanced non–small-cell lung cancer was conducted with pretreatment tumor collection for determination of RRM1 and ERCC1 expression by real-time reverse transcriptase polymerase chain reaction. The levels of gene expression were correlated with tumor response after two cycles of gemcitabine and carboplatin.

RESULTS: In cell lines with a genetically engineered 15-fold RRM1 expression range, the gemcitabine IC50 had a 100-fold range, and the cisplatin and carboplatin IC50 had a two-fold range. They were highest in constructs with high RRM1 expression. In the prospective clinical trial, RRM1 expression was significantly (P = .002) and inversely correlated (r = –0.498) with disease response. ERCC1 expression showed a similar trend (P = .099).

CONCLUSION: The results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy. ERCC1 expression is predictive of response albeit to a lesser degree.

published online ahead of print at www.jco.org on September 11, 2006.

Supported by Grants No. R01 CA102726 and R21 CA106616 from the National Cancer Institute.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S.-O. Kim, J.-Y. Jeong, M.-R. Kim, H.-J. Cho, J.-Y. Ju, Y.-S. Kwon, I.-J. Oh, K.-S. Kim, Y.-I. Kim, S.-C. Lim, et al.
Efficacy of Gemcitabine in Patients with Non-Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene
Clin. Cancer Res., May 15, 2008; 14(10): 3083 - 3088.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
D. Breen and F. Barlesi
The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 805 - 811.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
G. Bepler
Genes Predictive of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 350 - 352.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J.-C. Soria
ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2648 - 2649.
[Full Text] [PDF]


Home page
JCOHome page
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Cobo, D. Isla, B. Massuti, A. Montes, J. M. Sanchez, M. Provencio, N. Vinolas, L. Paz-Ares, G. Lopez-Vivanco, M. A. Munoz, et al.
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2747 - 2754.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
N. Engl. J. Med., February 22, 2007; 356(8): 800 - 808.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online